Zwiększanie biodostępności: określanie i podejścia koncepcyjne w przezwyciężaniu problemów biodostępności

Bioavailability measures the amount of unchanged drug reaching the systemic circulation after administration. It reflects both the extent and rate at which an active drug ingredient enters the bloodstream, remaining chemically unchanged. This metric is critical for determining a drug's efficacy and safety profile in patients.

The Biopharmaceutics Classification System categorizes drugs into four classes based on their solubility and permeability characteristics. This classification system aids in understanding drug absorption characteristics and guiding formulation strategies. Drugs with low solubility and permeability often face challenges with poor bioavailability that require targeted enhancement approaches.

Drug solubility is determined using pH-solubility profiling, which examines how solubility changes with pH, and shake-flask or titration methods, which determine solubility in different solvents or at various pH levels. These techniques help predict a drug's absorption characteristics and guide formulation development strategies for improving bioavailability.

Three primary approaches address poor bioavailability: the pharmaceutical approach modifies formulation, manufacturing, or physicochemical properties without changing chemical structure; the pharmacokinetic approach modifies the drug's chemical structure through prodrug designs or new chemical entities; and the biological approach changes the route of administration, such as switching from oral to parenteral routes.

Permeability is evaluated through mass-balance pharmacokinetic studies, in vivo intestinal perfusion studies, and permeation experiments using intestinal tissue or epithelial cell monolayers. These methods help predict a drug's absorption and bioavailability by assessing how effectively the drug crosses biological membranes in the gastrointestinal tract.

The pharmaceutical approach alters the drug's formulation, manufacturing process, or physicochemical properties without changing the molecular structure. This strategy can involve using solubilizers, reducing particle size, or forming amorphous solids to improve drug dissolution and absorption, thereby enhancing bioavailability without modifying the active ingredient itself.

The biological approach explores alternative routes of administration to bypass limitations associated with oral bioavailability. Switching from an oral to a parenteral route allows the drug to be administered directly into the systemic circulation, avoiding the gastrointestinal tract and its absorption barriers, thereby improving overall drug bioavailability and therapeutic effectiveness.